5mg + TB-500 5mg | Factory direct supply of peptide mixture, with favorable price
TDS
15990-43-9
Pharmaceutical Grade
99.6%
HK
Customization Available
10mg*10vials/box
2026-08-16
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceN-Benzylniacin(BPC) is a colorless to yellowish transparent liquid.Certificates
-
TDS
Basic Info-
Product Name:
N-Benzylniacin
Other Name:1-Benzyl-3-carboxypyridinium hydroxide inner salt;1-benzyl pyridinium-3-carboxylate;N-BENZYLNIACIN;N-BENZYLNICOTINAMIDE;N-Benzyl nicotinate betaine;N-Benzylpyridinium-3-carboxylate;pyridinium,3-carboxy-1-(phenylmethyl)-,hydroxide,innersalt;Pyridinium,3-carboxy-1-(phenylmethyl)-,innersalt
CAS No.:15990-43-9
Molecular Formula:C13H11NO2
InChIKeys:AVWFAACIXBQMBF-UHFFFAOYSA-N
Molecular Weight:213.24
Exact Mass:213.078979
EC Number:240-129-1
TSCA:TSCA listed
DSSTox ID:DTXSID0065989
Color/Form:light yellow
HScode:2933399090
Categories:
Characteristics-
PSA:
44
XLogP3:-2.74
Appearance:light yellow paste
Density:1.09
Refractive Index:1.625
Research-
Class:
Actin-sequestering protein / 43-amino-acid peptide
Status:Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)
Mechanism:A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.
Activity note:Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.
Source:Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI
Clinical Development:
References-
DrugBank:PubChem:UNII:Disclaimer:
Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Location:
2nd Floor, Room 0996, No. 963 Tianyuan Road, Tianhe District, Guangzhou
-
Average lead Time:
5
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
